mRNA Cancer Vaccines And Therapeutics Market Opportunities Are Emerging Beyond Traditional Growth Areas
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
mRNA Cancer Vaccines And Therapeutics Market Size, Value And Growth Trends Through 2030
The market for mRNA-based cancer vaccines and therapeutics has experienced significant expansion in recent years. Projected to rise from $71.22 billion in 2025 to $82.67 billion in 2026, this reflects a compound annual growth rate (CAGR) of 16.1%. During the historical period, this growth was driven by the proven effectiveness of mRNA platforms in infectious disease vaccines, progress in cancer immunology studies, a deeper comprehension of tumor antigens, preliminary clinical evidence supporting mRNA cancer treatments, and heightened investment from both public and private sectors in oncology research and development.
The market size for mRNA cancer vaccines and therapeutics is projected to experience significant expansion in the coming years. By 2030, it is anticipated to reach $141.51 billion, driven by a compound annual growth rate (CAGR) of 14.4%. This projected growth during the forecast period is influenced by factors such as the increasing global incidence of cancer, a rising demand for targeted and personalized treatment approaches, the enhancement of mRNA production capabilities, a higher number of oncology clinical trials employing mRNA platforms, and key strategic alliances formed between pharmaceutical and biotechnology companies. Among the prominent trends shaping this period are the growing acceptance of personalized cancer vaccines, the broadening use of mRNA-based treatments beyond the oncology field, an intensified focus on developing neoantigen-specific vaccines, a richer clinical pipeline for mRNA-driven cancer immunotherapies, and increased funding directed toward scalable facilities for mRNA manufacturing.
Download A Free Sample Report For Comprehensive Market Insights:
mRNA Cancer Vaccines And Therapeutics Market Demand Drivers Creating New Revenue Opportunities
The growing frequency of cancer cases is anticipated to accelerate the expansion of the mRNA cancer vaccine and therapeutic market in the coming years. Cancer refers to a set of illnesses defined by the unchecked proliferation and dissemination of abnormal cells, which have the capacity to invade and harm healthy tissue. This increase in cancer diagnoses is largely driven by lifestyle factors like physical inactivity, poor nutrition, and exposure to environmental contaminants, all of which heighten the likelihood of developing various forms of cancer. By facilitating customized and targeted immune responses that enable the body to more effectively recognize and destroy cancerous cells, mRNA cancer vaccines and therapeutics significantly enhance treatment outcomes. For example, in January 2024, the American Cancer Society, Inc., a US-based cancer advocacy group, reported that over 611,000 cancer-related deaths are projected in the United States for 2024, equating to more than 1,600 fatalities daily. Consequently, the rising burden of cancer is fueling growth in the mRNA cancer vaccine and therapeutic market.
mRNA Cancer Vaccines And Therapeutics Market Segment Analysis: What Are The Major Market Categories?
The mrna cancer vaccines and therapeutics market covered in this report is segmented –
1) By Type: Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas
2) By Application: Cancer, Other Applications
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Research Institutes, Other End Users
Subsegments:
1) By Adeno Carcinomas: Lung Adenocarcinomas, Colon Adenocarcinomas, Prostate Adenocarcinomas
2) By Mucinous Carcinomas: Mucinous Ovarian Cancer, Mucinous Breast Cancer, Mucinous Colorectal Cancer
3) By Adenosquamous Carcinomas: Pancreatic Adenosquamous Carcinoma, Cervical Adenosquamous Carcinoma, Esophageal Adenosquamous Carcinoma
mRNA Cancer Vaccines And Therapeutics Market Trends Driving Strategic Industry Expansion
Leading players in the mRNA cancer vaccines and therapeutics market are actively developing cutting-edge solutions, including personalized neoantigen vaccines, to boost immune responses and enhance survival rates for cancer patients. These vaccines are custom-made for each individual, leveraging distinct tumor-specific mutations to activate the immune system in targeting and eliminating cancer cells. For example, in July 2023, Merck & Co., Inc., a US-based research-driven biopharmaceutical firm, joined forces with Moderna Therapeutics, Inc., a US-based biotechnology company, to launch a Phase 3 randomized clinical trial (V940-001). This study investigates mRNA-4157 (V940) alongside KEYTRUDA (pembrolizumab) as an adjuvant therapy for patients with resected high-risk (Stage IIB-IV) melanoma. The initiative follows encouraging results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, which demonstrated a significant advantage of the combination over KEYTRUDA alone in lowering recurrence and distant metastasis risks. The Phase 3 trial seeks to validate these outcomes by evaluating relapse-free survival as the primary endpoint and distant metastasis-free survival as the secondary endpoint.
mRNA Cancer Vaccines And Therapeutics Market Leading Companies Driving Competitive Growth
Major companies operating in the mrna cancer vaccines and therapeutics market are BioNTech SE, Moderna Therapeutics Inc., CureVac N.V., Arcturus Therapeutics Holdings Inc., Immatics Biotechnologies GmbH, Argos Therapeutics Inc., Anima Biotech, Translate Bio, eTheRNA Immunotherapies NV, Gritstone bio Inc., Neon Therapeutics, Codiak BioSciences, Cartesian Therapeutics, Replimune Group Inc., Precision BioSciences, Acuitas Therapeutics, Ethris GmbH, Strand Therapeutics, Crown Bioscience, Roche (Hoffmann-La Roche AG)
Access The Complete mRNA Cancer Vaccines And Therapeutics Market Report:
mRNA Cancer Vaccines And Therapeutics Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the mRNA cancer vaccination and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna cancer vaccines and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
